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1 |  INTRODUCTION
Neuroendocrine neoplasms (NENs) constitute a hetero-
geneous group of neoplasms that can virtually arise in any 
organ of the body, but are most commonly found in the gas-
troenteropancreatic (GEP) tract and the lungs.1-3 NENs were 
first identified over a century ago by Siegfried Oberndorfer 
who introduced the term “Karzinoid” or “carcinoma-like” 
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Abstract
The incidence of neuroendocrine neoplasms (NENs) seems to increase worldwide. 
Long-term, population-based series that consider tumor differentiation are, how-
ever, sparse. We assessed the incidence trend of lung and gastroenteropancreatic 
(GEP) NENs according to the latest International Agency for Research on Cancer/
World Health Organization classification over a 41-year time period in two Swiss 
regions. All cases of lung and GEP NENs recorded in the Vaud and Neuchâtel Cancer 
Registries from 1976 to 2016 were included. NENs were stratified into well-differen-
tiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carci-
nomas (NECs). Changes in annual age-standardized incidence rates were calculated 
for lung and GEP NETs and NECs by sex. Of 4,141 patients diagnosed with NENs, 
65% were men. The incidence of lung NETs among men and women increased by 
3.9%/year (95% CI: −5.3, 14.1%) and 4.9%/year (0.1, 9.9%), respectively, between 
1976 and 2016. The incidence of lung NECs decreased by 2.6%/year (−3.1,-1.8%) in 
men from 1985 to 2016 whereas it increased in women between 1976 and 1998 by 
6%/year (4.2, 7.9%). For GEP NETs, a steady annual increase in incidence occurred 
between 1976 and 2016 with a magnitude of 1.7% (0.7, 2.7%) in men and 1.3% (0.5, 
2.1%) in women. No significant trend in incidence of GEP NECs was found for both 
sexes. The incidence trends of lung NECs in men and women parallel changes in 
smoking prevalence in the population. Causes of the increase in incidence of GEP 
NETs are likely multifactorial. Our study supports the importance of evaluating the 
epidemiology of NENs by tumor differentiation.
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to describe a slow-growing small bowel tumor.2 However, it 
became apparent that NENs can have a malignant behavior 
and therefore the term carcinoid is no longer recommended 
when referring to NENs.2 NENs are characterized by having 
neurosecretory granules4 and can secrete different hormones, 
which are frequently dependent on tumor site.
Small bowel NENs most often secrete serotonin and 
kallikrein, which can give rise to a characteristic paraneo-
plastic syndrome referred to as the “carcinoid syndrome.”4-6 
In the pancreas, tumors may secrete pancreatic hormones or 
gastrin, a hormone that is frequently secreted by duodenal 
NENs. However, the carcinoid syndrome and the specific en-
docrine syndromes related to the secretion of the above-men-
tioned hormones (glucagonomas, somatostatinomas, 
Zollinger-Ellison syndrome, among others) are only present 
in a minority of cases and the vast majority of NENs are diag-
nosed because of bowel obstructions, pulmonary symptoms, 
local growth, metastatic disease, or as incidental findings.5,7,8
Over the years, the numerous and changing nomenclature 
and grading systems have led to confusion among clinicians 
and pathologists.2 Changes in the classification systems of 
NENs are summarized in Table 1. In 2018, the World Health 
Organization (WHO) and the International Agency for 
Research on Cancer (IARC) proposed unifying nomencla-
tures to classify NENs into well-differentiated NENs, or neu-
roendocrine tumors (NETs), and poorly differentiated NENs, 
or neuroendocrine carcinomas (NECs).4 This classification, 
officially adopted in the last WHO classification of digestive 
NENs,9 has clinical utility as it can help better define tumor 
prognosis and guide management.2 NETs can be further clas-
sified into grades 1-3 using three parameters: mitotic count, 
the Ki-67 cell labeling index for GEP NETs, and in the lung, 
where the term carcinoid is still accepted, the presence or 
absence of necrosis.4
The incidence of NENs seems to increase worldwide 
but the magnitude of the trend varies widely across stud-
ies.1,3,5,6,10-19 This is likely due to the rarity and hetero-
geneity of these tumors, differences in data sources used 
(hospital-based vs. population-based series), changes in the 
classification and nomenclature used over time, as well as 
variability in ascertainment.12 For example, in the United 
States, the age-adjusted incidence rate for NENs increased 
more than sixfold between 1973 and 2012 (from 1.1 to 7 per 
100,000),11 while in the Netherlands a doubling of the inci-
dence has been observed between 1990 and 2010 (from 2.1 
to 4.9 per 100,000)13.
Despite the increasing number of publications on NENs 
in recent years, most studies could not assess the incidence 
of NENs from a population-based perspective, did not report 
incidence rates by tumor differentiation or histological grade, 
and were conducted over a limited time period. Therefore, the 
current study aims at evaluating the incidence trend of lung 
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classification over a 41-year time period in two Swiss pop-
ulations, based on long-established and high-quality cancer 
registry data.20
2 |  MATERIALS AND METHODS
Data for this study were extracted from the population-
based Vaud and Neuchâtel Cancer Registries which col-
lect, document, and record all new cancer cases diagnosed 
among their resident populations since 1974 (total popu-
lation in 2016: 951,514).21 Ascertainment of most cases 
is derived from multiple sources and cancer registration 
has a high level of completeness.20 Recorded data include 
demographic characteristics, primary tumor site, and mor-
phology according to the International Classification of 
Diseases for Oncology (ICD-O-1 to ICD-O-3). All cases of 
lung (ICD-O topography codes: C34.0 - C34.9) and GEP 
(ICD-O topography codes: C15.0 - C25.9) NENs diag-
nosed over the 41-year period 1976-2016 were included in 
our analyses.
Tumor grade was available in 24% of cases because re-
porting proliferation indexes of tumors were only recently 
introduced routinely. Instead, we used the WHO/IARC 
recommendations to divide NENs into well-differentiated 
NETs and poorly differentiated NECs.4 Cases registered as 
typical carcinoid tumors, enterochromaffin cell and enter-
ochromaffin-like cell carcinoid tumors, tubular carcinoids, 
atypical carcinoids, islet cell carcinomas, insulinomas, 
glucagonomas, gastrinomas, vipomas, somatostatinomas, 
and enteroglucagnomas were classified as NETs (ICD-O-
3: 8240-42, 8245, 8249, 8150-53, and 8155-57). Large and 
small cell NECs, and NECs not otherwise specified (NOS) 
were classified as NECs (ICD-O-3: 8013, 8041-44, and 
8246). Goblet cell carcinoids (ICD-O-3: 8243) were not 
included as they are now considered low-grade adenocar-
cinomas according to the 2019 WHO classification for di-
gestive tumors.22 To circumvent changes in morphological 
classifications over time, we re-categorized NENs accord-
ing to the 2013 ICD-O-3.1 classification, even for tumors 
diagnosed before this date. NENs previously diagnosed as 
grade 1 NECs and as grade 2 NECs were thus recoded as 
8240 (rather than 8246) and as 8249 (rather than 8246), 
respectively.
Cases were analyzed by sex, age and year of diagnosis, 
tumor type (NET vs. NEC), and tumor site (lung vs. GEP). 
Age-standardized incidence rates per 100,000 per year were 
calculated using the 1976 European standard population. We 
fitted a log-linear regression model to estimate the annual 
percent change in the standardized rates, with calendar year 
as the predictor variable. Joinpoint statistical software (ver-
sion 4.3; Surveillance Research Program, National Cancer 
Institute, Bethesda, MD) was used to estimate the model 
parameters, and to provide their standard errors allowing for 
heteroscedasticity management and calculation of confidence 
intervals for annual percent change in age-standardized inci-
dence rates. For GEP NECs, trend analyses were restricted 
to the time period 1996-2016 for men and 1998-2016 for 
women due to an insufficient number of cases before these 
years.
3 |  RESULTS
There were 4141 patients diagnosed with NENs in these two 
Swiss regions between 1976 and 2016, of which 65% were 
men. The median age at diagnosis was 65 years (interquartile 
range: 57-73) for men and 64 years for women (interquartile 
range 52–73). Table 2 presents the distribution of the 3041 
lung and 1100 gastroenteropancreatic NENs by morphologi-
cal type. Most lung NETs were typical carcinoids (91% of 
cases). In the lungs, 95% of NECs were small cell lung carci-
nomas (SCLC), whereas 62% of GEP NECs were registered 
as NEC, NOS.
There was a slight female preponderance in NET cases 
(54% and 51% for lung and GEP, respectively), whereas 
NECs patients were more often men (72% and 58% for lung 
and GEP NECs, respectively). The majority of GEP NETs 
were located in the small intestine (33%) or the appendix 
(30%) (Figure 1). The most common site for GEP NECs was 
the pancreas (28%).
Figure 2 displays the age-standardized incidence rates of 
lung and GEP NENs by sex and quinquennial time period. 
Among men, the incidence of lung NENs decreased from 16.3 
cases per 100,000 in 1976–1980 to 9.2 cases per 100,000 in 
2011–2016, whereas the opposite trend was observed among 
women (increase from 1.5 cases per 100,000 in 1976–1980 
to 6.2 cases per 100,000 in 2011–2016). However, the in-
cidence rate of lung NENs remained higher in men than in 
women. For GEP NENs, there was an upward trend in both 
sexes (from 2.4 cases per 100,000 in 1976–1980 to 4.5 cases 
per 100,000 in 2011–2016 among men and from 2.3 cases per 
100,000 in 1976–1980 to 4.2 cases per 100,000 in 2011–2016 
among women).
The age-standardized incidence rates of lung and GEP 
NENs by sex, 5-year time period, and tumor type (NET vs. 
NEC) are reported in Table 3.
The trends in incidence rates from 1976 to 2016 of lung 
and GEP NENs by sex and tumor type are displayed in Table 
4. The incidence of lung NENs among men increased non 
significantly by 4.9% (95% confidence interval (CI): −3 to 
13.4) per year between 1976 and 1981 and gradually de-
creased thereafter by 2.2% per year (95% CI: −2.7 to −1.8). 
In contrast, the incidence of lung NENs in women increased 
between 1976 and 1998 by 5% per year (95% CI: 3.1 to 6.9), 
before stabilizing. For GEP NENs, a steady annual increase 
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in incidence occurred between 1976 and 2016 with a magni-
tude of 2.2% in men (95% CI: 1.4 to 3.1) and 1.8% in women 
(95% CI: 1.0 to 2.7).
The incidence of lung NETs (carcinoids) did not reveal 
any significant trend in men, but increased in women by 4.9% 
(95% CI: 0.1 to 9.9) per year between 1976 and 2016. For 
lung NECs, a decrease in the incidence of 2.6% per year has 
been observed in men (95% CI: −3.1 to −2) between 1985 
and 2016 whereas the incidence has increased in women be-
tween 1976 and 1998 by 6% per year (95% CI: 4.2 to 7.9), 
after which it stabilized. For GEP NETs, the incidence has 
moderately but significantly increased in both men and 
women between 1976 and 2016 at a rate of 1.7% per annum 
in men (95% CI: 0.7 to 2.7) and 1.3% per annum in women 
(95% CI: 0.5 to 2.1). GEP NECs did not show an incidence 
trend for both sexes.
4 |  DISCUSSION
In this population-based study from two Swiss cancer reg-
istries, we assessed the incidence trend of lung and GEP 
NENs over four decades using the most recent WHO/IARC 
classification. We observed a decrease in incidence of lung 
NENs in men between 1981 and 2016 mostly explained 
by the downward trend in lung NECs. Among women, 
the incidence of lung NENs increased from 1976 to 1998 
driven by a rise in both lung NETs and NECs. This was fol-
lowed by a stabilization in incidence in lung NENs mainly 
due to a stable incidence of lung NECs. Incidence of GEP 
NENs has steadily increased by the same magnitude in 
both men and women between 1976 and 2016 due to an 
increase in GEP NETs.
Only few studies have analyzed the incidence trend of 
NENs according to tumor differentiation.13,15,23 It is notewor-
thy that NETs and NECs are two distinct disease entities in 
terms of histological characteristics, and they have a different 
molecular background, tumor biology, prognosis, and treat-
ment.2,4 Moreover, NETs predominate at some sites (e.g., in 
the small intestine) whereas NECs constitute the majority of 
NENs in other organs.4 This is consistent with our findings 
that most GEP NENs were NETs, whereas the majority of 
lung NENs were NECs.
In regards to morphology, the vast majority of lung NETs 
(carcinoids) were typical carcinoids, consistent with the lit-
erature.24 We observed a significant increase of 5% per year 
between 1976 and 2016 in lung NET incidence in women 
and of 4.9% per year in men (though statistically non-signif-
icant). Previous studies have also shown an increase in lung 
NETs over time,1,11,15,25 although a sex difference in inci-
dence trends for lung NETs is rarely reported. Leoncini et al. 
found a higher trend in incidence rate of lung NETs among 
T A B L E  2  Distribution of lung and gastroenteropancreatic neuroendocrine neoplasms between 1976 and 2016 in two Swiss regions by tumor 
type.
Lung NENs GEP NENs Total
Distribution Distribution Distribution
Tumor type n % n % n %
NET, total 225 7.4 962 87.5 1187 28.7
Carcinoid tumor 204 90.7 827 86.0 1031 86.9
Enterochromaffin cell carcinoid 2 0.9 27 2.8 29 2.4
Enterochromaffin-like cell carcinoid 1 0.4 10 1.0 11 0.9
Tubular carcinoid - - 5 0.5 5 0.4
Atypical carcinoid 18 8.0 46 4.8 64 5.4
Islet cell carcinoma - - 6 0.6 6 0.5
Insulinoma - - 25 2.6 25 2.1
Glucagonoma - - 7 0.7 7 0.6
Gastrinoma - - 8 0.8 8 0.7
Somatostatinoma - - 1 0.1 1 0.1
NEC, total 2816 92.6 138 12.6 2954 71.3
Small cell carcinoma 2670 94.8 41 29.7 2711 91.8
Large cell carcinoma 90 3.2 11 8.0 101 3.4
NEC, NOS 56 2 86 62.3 142 4.8
Abbreviations: GEP, gastroenteropancreatic; NEC, neuroendocrine carcinomas; NEN, neuroendocrine neoplasms; NET, neuroendocrine tumors; NOS, not otherwise 
specified.
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women versus men in the Surveillance, Epidemiology, 
and End Results (SEER) program in the Unites States.15 
Conversely, in the Netherlands a decreasing incidence of lung 
NETs (carcinoids) in men over time and a stable incidence in 
women has been reported.13 As risk factors for lung NETs 
(carcinoids) are still largely unidentified, it remains uncertain 
whether this increase in incidence could be due to changes 
in exposure to putative risk factors. In particular, it remains 
unclear whether smoking is associated with lung NETs (car-
cinoids).13 It has also been postulated that the increase in 
imaging procedures might be responsible for the observed 
increase in lung NETs (carcinoids).11
Concerning the incidence trend of lung NECs, we ob-
served a decrease of 2.6% per year in men from 1985 to 2016 
and a strong increase of 6% per year in women from 1976 to 
1998, followed by a plateau. The majority of our lung NECs 
were SCLC, which is a cancer strongly associated with smok-
ing.26 Large cell lung cancer is also associated with smok-
ing27. Studies focusing on NENs often exclude SCLC based 
on their different biological and histological properties as 
compared to other NENs. Studies that included SCLC also 
found that SCLC was the most common lung NEC and re-
ported sex-specific trends in incidence similar to our find-
ings.13,15,23,25,26 These trends are consistent with smoking 
habits as the prevalence of tobacco use among women lags 
behind that of men by a few decades.28 This can explain the 
upward incidence trend of lung NECs among women up to 
1998, whereas the incidence in men has been decreasing 
since around 1985 in the two Swiss regions covered in our 
analysis.
Our finding that the incidence of GEP NETs has been 
steadily increasing for over four decades concurs with the 
literature.13,15 In line with previous studies, most GEP NETs 
were located in the small intestine and the appendix.13,17,23 
An earlier study in the Vaud population also reported an 
increase in GEP NETs incidence between 1974 and 1997 
mainly among men.16 Although an increase in incidence of 
GEP NECs is apparent over time, this trend did not reach 
statistical significance. Studies that have reported incidence 
trends of GEP NENs by level of differentiation (NETs vs. 
NECs) have shown an upward trend in the incidence of GEP 
NECs.13,15 Our study might be underpowered to detect a sig-
nificant change in incidence due to the relatively small num-
ber of GEP NEC cases.
Whether the increase in incidence in GEP NENs reported 
in several international studies is true or spurious remains un-
clear. Some have attributed the increase in GEP NETs to the 
increased use of endoscopies and radiological procedures, 
and an increased medical sensitivity in regards to these neo-
plasms.13,23 In Switzerland, the use of computed tomography 
scans has more than doubled between 1998 and 2008, which 
could explain the increased detection rate for NENs.29 This 
may be particularly true for small, noninvasive tumors that 
might not have been otherwise detected.23 This assumption 
is consistent with our results as the incidence of well-differ-
entiated GEP NETs rises, while that of poorly differentiated 
GEP NECs does not. In support of this assumption, a recent 
Canadian study has shown a rising incidence of NETs con-
comitant with a decreased incidence of metastatic NENs.6
Other possible contributory factors for the rising inci-
dence of GEP NETs are the changes in both morphological 
and clinical classification systems, and an increased aware-
ness of NENs among pathologists and clinicians.13,30 For 
example, the term “well-differentiated neuroendocrine car-
cinoma” introduced in the 2000 WHO classification to de-
fine metastatic well-differentiated neuroendocrine neoplasm 
created some confusion.31 Indeed, it was intended to define a 
well-differentiated tumor now categorized as NET. The term 
NEC is now only applicable to a poorly differentiated neuro-
endocrine neoplasm. Introduction of immunohistochemistry 
methods might have also contributed to this rising incidence 
as these methods facilitate the diagnosis of NEN cases for 
pathologists,30 although this should increase the incidence of 
all GEP NENs and not only of GEP NETs.
If the increase in GEP NENs were solely explained by a rise 
in incidental discoveries or increased awareness, then one would 
expect the incidence of all GEP NENs to increase in the same 
F I G U R E  1  Anatomic distribution (%) of gastroenteropancreatic 
(GEP) neuroendocrine tumors (NET) tumors (A) and GEP 
neuroendocrine carcinomas (NEC) tumors (B) by site
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F I G U R E  2  Age-standardized incidence rates of neuroendocrine neoplasms (NENs) by 5-year intervals and sex in the lung (A) and 
gastroenteropancreatic (GEP) tract (B). Rates are per 100,000 and age-adjusted to the 1976 European standard population.
T A B L E  3  Age-standardized incidence rates of neuroendocrine neoplasms by 5-year intervals, sex, and tumor type in the lung and 
gastroenteropancreatic (GEP) tract by tumor type. Rates are per 100,000 and age-adjusted to the 1976 European standard population
Incidence year interval
Men Women
Lung GEP Lung GEP
NET NEC NET NEC NET NEC NET NEC
1976–1980 0.60 15.73 2.26 0.16 0.39 1.14 2.27 0.03
1981–1985 0.48 16.66 1.60 0.17 0.64 2.60 1.87 0.05
1986–1990 0.26 17.09 2.96 0.13 0.47 2.48 2.78 0.00
1991–1995 0.63 13.69 2.65 0.11 0.42 3.92 2.12 0.02
1996–2000 1.27 10.86 2.36 0.58 0.59 4.77 2.05 0.24
2001–2005 0.45 10.84 2.32 0.56 0.37 5.21 2.41 0.46
2006–2010 0.46 9.27 4.21 0.62 0.71 4.70 3.10 0.60
2011–2016 0.74 8.50 3.55 0.90 1.19 5.05 3.70 0.50
Abbreviations: GEP, gastroenteropancreatic; NET, neuroendocrine tumors; NEC, neuroendocrine carcinomas.
9460 |   ALWAN et AL.
proportion.12 However, the reported magnitude of incidence 
trends of GEP NENs varies by organ.12 If there is a true rise in 
incidence of these neoplasms, the underlying factors and mech-
anisms remain to be elucidated. It has been suggested that the 
rising incidence of gastric NETs may be due to the increased use 
of proton pump inhibitors during the last decades.12
Our study has some limitations. We did not estimate the 
incidence of GEP NENs by organ due to the limited num-
ber of cases. Data on grade and stage were incomplete. To 
overcome this, we divided NENs into well-differentiated and 
poorly differentiated neoplasms according to the latest WHO/
IARC classification. Strengths of our study include its popu-
lation-based nature with a long follow-up of 41 years and a 
high degree of registration completeness. Moreover, in con-
trast to most cancer registries that historically included only 
malignant tumors, the Vaud and Neuchâtel cancer registries 
have recorded all NENs since their establishment, despite 
the fact that some NEN types were initially considered as be-
nign neoplasms. This strongly reduces the risk of bias due 
to changes in pathological classification criteria in incidence 
trend analyses.
In conclusion, the findings of this study support the impor-
tance of evaluating the epidemiology of NENs by their level 
of differentiation. The incidence trends of lung NECs in men 
and women parallel the changes in smoking prevalence in the 
population. Causes of the steady increase in incidence of GEP 
NENs over the last four decades are not fully understood and 
are likely multifactorial. Future studies should ideally use pop-
ulation-based data, apply the latest WHO/IARC classifications 
for NENs, and have complete information on histological grade 
and stage in order to better identify some of the reasons under-
lying the changes in the incidence trends of NENs.
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T A B L E  4  Trends in the incidence rate of neuroendocrine neoplasms from 1976 to 2016.
NEN category
Trend 1 Trend 2
Years EAPC (%) 95% CI (%) Years EAPC (%) 95% CI (%)
Lung NENs
Men 1976-1981 4.9 −3 to 13.4 1981-2016 −2.2 −2.7 to −1.8
Women 1976-1998 5 3.1 to 6.9 1998-2016 0.7 −0.8 to 2.2
GEP NENs
Men 1976-2016 2.2 1.4 to 3.1
Women 1976-2016 1.8 1.0 to 2.7
Lung NETs
Men 1976-2016 3.9 −5.3 to 14.1
Women 1976-2016 4.9 0.1 to 9.9
Lung NECs
Men 1976-1985 1.3 −2.1 to 4.9 1985-2016 −2.6 −3.1 to −2
Women 1976-1998 6 4.2 to 7.9 1998-2016 0 −1.4 to 1.4
GEP NETs
Men 1976-2016 1.7 0.7 to 2.7
Women 1976-2016 1.3 0.5 to 2.1
GEP NECs
Men 1996-2016 6.7 −6.7 to 22
Women 1998-2016 5.4 −12.1 to 26.4
Abbreviations: EAPC: estimated annual percentage change; GEP: gastroenteropancreatic; NEC: neuroendocrine carcinomas; NEN: neuroendocrine neoplasms; NET: 
neuroendocrine tumors.
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